Prevas AB Series B
Prevas AB provides technical solutions in Sweden, Denmark, Finland, and internationally. The company offers embedded systems and intelligent sensors, enterprise asset management maintenance solutions, field service, industrial digitalization, internet of things, product development of medical technology products, product lifecycle management, and smart services; and cyber security, electronics de… Read more
Prevas AB Series B (0H2J) - Net Assets
Latest net assets as of September 2021: Skr430.74 Million SEK
Based on the latest financial reports, Prevas AB Series B (0H2J) has net assets worth Skr430.74 Million SEK as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr781.23 Million) and total liabilities (Skr350.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr430.74 Million |
| % of Total Assets | 55.14% |
| Annual Growth Rate | 13.85% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.22 |
Prevas AB Series B - Net Assets Trend (2016–2020)
This chart illustrates how Prevas AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prevas AB Series B (2016–2020)
The table below shows the annual net assets of Prevas AB Series B from 2016 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | Skr229.78 Million | +23.00% |
| 2019-12-31 | Skr186.81 Million | +21.53% |
| 2018-12-31 | Skr153.71 Million | +4.39% |
| 2017-12-31 | Skr147.25 Million | +7.68% |
| 2016-12-31 | Skr136.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prevas AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 163.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr149.95 Million | 65.26% |
| Common Stock | Skr25.26 Million | 10.99% |
| Other Components | Skr54.57 Million | 23.75% |
| Total Equity | Skr229.78 Million | 100.00% |
Prevas AB Series B Competitors by Market Cap
The table below lists competitors of Prevas AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Central Plains Bancshares, Inc. Common Stock
NASDAQ:CPBI
|
$48.55 Million |
|
AMIA Co. Ltd.
TW:8438
|
$48.56 Million |
|
Stratec SE
PINK:STSEY
|
$48.57 Million |
|
Oncopeptides AB (publ)
PINK:ONPPF
|
$48.58 Million |
|
Sanstar Ltd
NSE:SANSTAR
|
$48.55 Million |
|
Imas Makina Sanayi AS
IS:IMASM
|
$48.54 Million |
|
MKH Bhd
KLSE:6114
|
$48.51 Million |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
$48.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prevas AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 186,807,000 to 229,780,000, a change of 42,973,000 (23.0%).
- Net income of 45,933,000 contributed positively to equity growth.
- Dividend payments of 25,473,000 reduced retained earnings.
- Other factors increased equity by 22,513,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr45.93 Million | +19.99% |
| Dividends Paid | Skr25.47 Million | -11.09% |
| Other Changes | Skr22.51 Million | +9.8% |
| Total Change | Skr- | 23.00% |
Book Value vs Market Value Analysis
This analysis compares Prevas AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Prevas AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.99%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.95%
- • Asset Turnover: 1.70x
- • Equity Multiplier: 1.98x
- Recent ROE (19.99%) is above the historical average (8.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -5.39% | -1.06% | 1.92x | 2.65x | Skr-21.04 Million |
| 2017 | 7.25% | 1.45% | 2.02x | 2.47x | Skr-4.05 Million |
| 2018 | 2.98% | 0.59% | 2.08x | 2.42x | Skr-10.79 Million |
| 2019 | 17.09% | 4.01% | 1.99x | 2.14x | Skr13.24 Million |
| 2020 | 19.99% | 5.95% | 1.70x | 1.98x | Skr22.95 Million |
Industry Comparison
This section compares Prevas AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prevas AB Series B (0H2J) | Skr430.74 Million | -5.39% | 0.81x | $48.55 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |